Eli Lil­ly to dou­ble its man­u­fac­tur­ing ca­pac­i­ty for Moun­jaro as it faces fi­nan­cial head­winds go­ing in­to 2023 — re­port

Eli Lil­ly is fac­ing sev­er­al fi­nan­cial head­winds go­ing in­to next year, spurred by the dry­ing up of Covid-19 an­ti­body sales and sup­ply con­straints, ac­cord­ing to a re­port from SVB Se­cu­ri­ties by three of its an­a­lysts who vis­it­ed Eli Lil­ly’s head­quar­ters in In­di­anapo­lis last week.

An an­tic­i­pat­ed “step­down” in Covid-19 an­ti­body sales, af­ter about $2 bil­lion in re­cent sales, due to a lack of pro­tec­tion against the new­er vari­ants, as well as oth­er speed­bumps like Al­im­ta gener­ics, pres­sure from in­fla­tion and in­cre­men­tal costs for man­u­fac­tur­ing were cit­ed as po­ten­tial head­winds.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.